Testing binimetinib for BRAF fusion brain tumors and pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a targeted drug, binimetinib, for people with low-grade glioma (a type of brain tumor) or pancreatic cancer that has a specific genetic change called a BRAF fusion. The drug aims to block signals that help these tumors grow.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a low-grade glioma (brain tumor) that is slow-growing or pancreatic cancer that has spread or cannot be removed by surgery.
- A genetic test shows you have a BRAF fusion or rearrangement in your tumor.
- You are at least 12 years old and weigh at least 40 kg (about 88 pounds) for the brain tumor group, or at least 18 for the pancreatic cancer group.
- You have not had chemotherapy in the last 14 days, or other targeted or immune therapy in the last 21 days.
- Your heart, liver, kidney, and blood cell counts are within certain safe ranges (checked by blood tests and an echocardiogram).
- You are willing to use effective contraception during and for a time after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two targeted drugs (dabrafenib and trametinib) for children and young adults with a specific type of low-grade brain tumor that has a BRAF V600 mutation. The drugs work by blocking signals that help the tumor grow.
This trial tests a combination of targeted therapy (dabrafenib and trametinib) and immunotherapy (nivolumab) for children and young adults with certain BRAF gene changes in their glioma. It aims to see if this drug combination can shrink tumors or stop them from growing.
This Phase 1 trial studies how PF-07799544 works and what dose is safest in people with advanced cancer that has a specific genetic change called BRAF V600. You may receive it alone or with another treatment, depending on the tumor group, to see if it can treat the cancer.
This trial tests whether a new oral drug called FCN-159 works better than standard chemotherapy for children and teens with a slow-growing brain tumor (low-grade glioma) that has a specific change in the BRAF gene. The goal is to see if FCN-159 can shrink the tumor or stop it from growing.
This Phase 1 trial studies PF-07799933, a new medicine, in people whose advanced solid tumors have specific BRAF genetic changes. It may help if your cancer has continued to grow after standard treatments, and there may be specific options depending on your cancer type and past therapies.
This trial tests a drug called Belvarafenib for people with brain tumors that have a BRAF gene change (mutation). The drug targets this specific change to try to shrink or control the tumor. It is for patients whose brain tumor has come back or hasn't responded to other treatments.
Hear when a new Low-grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.